327 results about "Vancomycin" patented technology

A method of administering an aerosolized anti-infective, such as a glycopeptide, to the respiratory system of a patient. A ratio of an amount of the glycopeptide, such as vancomycin, delivered to the pulmonary system of the patient in a 24 hour period to a minimum inhibitory amount for the target organ for the same period is about 2 or more. A system to introduce aerosolized medicament to a patient may include a humidifier coupled to an inspiratory limb of a ventilator circuit wye, where the humidifier supplies heated and humidified air to the patient, and an endotracheal tube having a proximal end coupled to a distal end of the ventilator circuit wye. The system may also include a nebulizer coupled to the endotracheal tube, where the nebulizer generates the aerosolized medicament.

There is disclosed herein a composition for treating gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhea, chronic idiopathic nausea, IBD-associated constipation and diarrhea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinsons disease, MS, Alzheimers Disease, Motor Neurone Disease or autism, the composition comprising: (i) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (ii) at least one anti-clostridial agent selected from the above combined with an opioid blocking agent. There is also disclosed herein a method of treating various gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhea, chronic idiopathic nausea, IBD-associated constipation and diarrhea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinsons disease, MS, Alzheimers Disease, Motor Neurone Disease or autism, the method comprising administering orally, via enema or by suppository: (i) a composition of the invention; (ii) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (iii) at least one anti-clostridial agent selected from the above and an opioid blocking agent to a patient in need of such treatment.

The invention relates to a new type antibiotic containing an antibody analog, a preparation method and an application method thereof, which belong to the field of biological medicaments. The new type antibiotic containing an antibody analog comprises colicin E1, Ia, Ib, A, B, N or a water pore canal domain thereof and an antibody analog, wherein the antibody analog is formed by connecting the carboxyl terminal of VHCDR1 of immunoglobulin with the amidogen terminal of VHFR2 and connecting the carboxyl terminal of VHFR2 with the amidogen terminal of VLCD; and porin is identified specifically by the immunoglobulin. The sterilization capability of the antibiotic is thousands of times of that of commonly used antibiotics. Because the action mechanism is special, pathogen is difficult to produce medicament resistant property; human normal cells are not harmed in the process of sterilization; and the new type antibiotic containing an antibody analog can be used for preparing medicaments of resisting meningococcus, vancocin enterococcus, methicillin staphylomycin or multi-medicament resistant cyanomycosis.

The present disclosure relates in part to liposomal vancomycin compositions having low lipid to drug ratios and high concentration of vancomycin. The present disclosure also relates in part to methods of making such compositions.

The present disclosure relates in part to methods of treating and prevention of pulmonary disorders in a subject in need thereof comprising administering to the subject a liposomal vancomycin compositions having low lipid to drug ratios and high concentration of vancomycin.

Vancomycin-polymer conjugates are disclosed. In preferred aspects, polymer residues which are hydrolysis resistant in vitro, are selectively attached to the sugar amino and / or N-methyl amino groups of vancomycin and related compounds. Vancomycin-polymer conjugates made by the methods and methods of treatment using the conjugates are also disclosed.

The present invention relates to the role of the microbiota in the efficacy of cancer treatments with a drug blocking an. immune checkpoint and provides methods and probiotics to improve the efficacy of such a treatment in patients in need thereof. More particularly, the invention pertains to the use of vancomycin or penicillin to modulate the gut microbiota to potentiate the anticancer effects of anti-CTLA4 molecules. B. fragilis or fecal microbial transplantation of a defined composition enriched in immunogenic Bacteroides spp. can also be used as a probiotic to that aim.

The invention discloses a preparation method for an anti-infectious nano collagen / calcium phosphate bone repair material, and belongs to the field of biomedical materials. The method comprises the following steps of: slowly dripping solution containing calcium ions and aqueous solution containing phosphate radical ions into acid-soluble collagen solution, dripping NaOH solution to regulate the pH value, performing freeze drying, grinding to obtain dry powder for later use, dissolving poly-L-lactic acid in 1,4-dioxane, stirring for a certain time, mixing the solution and the dry powder uniformly, finally adding vancomycin, stirring uniformly, removing the solvent by adopting a freeze drying method, and preparing the anti-infectious nano collagen / calcium phosphate bone repair material. The prepared bone repair material has excellent biocompatibility, infection resistance and a micro-structure similar to human body.

This invention provides a method of detecting pathogens comprising the steps of: (a) contacting a sufficient amount of biofunctional magnetic nanoparticles with an appropriate sample for an appropriate period of time to permit the formation of complexes between the pathogens in the sample and the nanoparticles; (b) using a magnetic field to aggregate said complexes; and (c) detecting said complexes. The method may further comprise the additional step of removing said complexes. The biofunctional magnetic nanoparticles are preferably a conjugate of vancomycin and FePt. The pathogens may be bacteria or viruses, and the sample may be a solid, liquid, or gas. Detection may involve conventional fluorescence assay, enzyme-linked immunosorbent assay (ELISA), optical microscope, electron microscope, or a combination thereof. The sensitivity of detection for the method is at least as low as 10 colony forming units (cfu) of the pathogens in one milliliter of solution within one hour.

The invention discloses a novel treatment process of antibiotic wastewater electron beams. The process is characterized by comprising the following steps of: irradiating electron beams, taking an antibiotic wastewater (500-1000mL) sample, adding 0.5%o-2%o of irradiating synergistic agent, mixing uniformly, conveying by using a tray, and irradiating by using a transmission system under the beam of an electron accelcrator; (2) carrying out coagulating sedimentation, adding 0.2%o - 0.4%o of flocculant into an irradiated water sample, quickly stirring for reacting, adding 0.4%o -0.7%o of coagulant aid, slowly stirring to form alumen ustum, standing for settling for 30 -60min, loading supernate by using a sterile bottle, conserving at temperature of 5oC -8oC, and conveying to the detection place to carry out detection analysis on the concentration of vancomycin and biological value; and (3) carrying out result analysis in which biological value is 0.5%, removal rate is 98.7%, vancomycin in mother solution is lower than a detection limit, and the biotoxicity of wastewater is obviously reduced.

In one aspect, the invention provides a stabilized lipid-based glycopeptide antibiotic composition and a process for producing the same. In another aspect, the invention provides methods for treating a bacterial pulmonary infection by administering to a subject in need thereof a therapeutically effective amount of the stabilized lipid-based glycopeptide antibiotic composition.

The invention relates to a drug-loading sustained-release support composite body for treating infectious bone defect. The drug-loading sustained-release support composite body is prepared by the stepthat vancomycin is encapsulated by polylactic acid-glycolic acid copolymer to prepare sustained release microspheres and loaded to a beta-tricalcium phosphate support. The vancomycin, with broad-spectrum antibacterial capacity, is encapsulated by the polylactic acid-glycolic acid copolymer to prepare into sustained microspheres, and loaded to the beta-tricalcium phosphate support to prepare a novel drug-loading sustained-release anti-infection bone substitute material which can slowly release the vancomycin at a part of the infectious bone defect. When being applied to treating the infectiousbone defect, the material can release the encapsulated vancomycin in an all-dimensional mode for a long time in a partial three-dimensional space of the infectious bone defect after being embedded; thus, the purpose of controlling infection within the focus of infection is achieved; meanwhile, the effects of filling bone defect, promoting bone formation and quickening bone reconstruction are achieved.

The invention describes a pharmaceutical composition to combat multiple-drug-resistant bacteria in non-ocular infective conditions. Compositions comprising glycopeptides, in particular vancomycin, and cephalosporins, in particular ceftriaxone, are disclosed. Such compositions are found to be useful for parenteral administration for hospitalized patients with serious infections. Specifically, this invention also discloses a pharmaceutical composition further including an excipient such as CVMC agent and is available in dry powder form for reconstitution before injection with a suitable solvent. The pharmaceutical compositions of this invention have been found normally to enhance resistance to precipitation in solutions to be administered parenterally. The invention also gives details of the dosage forms stored in sealed containers to be reconstituted before use. The invention further provides a process to manufacture these compositions and also a method of treating a subject having non-ocular infective conditions due to multi drug resistant bacterium.